Health Catalyst, Inc. reported strong financial results for the fourth quarter and full year ended December 31, 2024. For the full year 2024, total revenue reached $307 million, and Adjusted EBITDA was $26 million, demonstrating solid operational performance.
The Technology segment showed particular strength, with revenue of $52 million for the fourth quarter of 2024, representing a 10% year-over-year growth. The company anticipates a continued reacceleration of topline growth for full year 2025, with the Technology segment expected to grow faster than the total business.
For full year 2025, Health Catalyst projects total revenue of approximately $335 million and technology revenue of approximately $220 million, representing about 13% year-over-year growth. The company also raised its target for 2025 Adjusted EBITDA by $2 million, now expecting approximately $41 million, reflecting continued focus on profitability and operating leverage. Additionally, Dr. Daniel Samarov was promoted to Chief AI Officer, and Dr. Jill Hoggard Green joined the Board of Directors on December 1, 2024.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.